Last updated on December 2019

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients


Brief description of study

The purpose of the study is to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET).

Clinical Study Identifier: NCT03049189

Find a site near you

Start Over

Universit tsklinikum Erlangen

Erlangen, Germany
8.68miles
  Connect »